Oruka Therapeutics (NASDAQ:ORKA) Stock Keeps “Buy” Rating at BTIG ResearchDefense World · 5 days ago
Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far EndSeeking Alpha · 6 days ago
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy DataZacks Investment Research · Sep 24, 2026
Oruka Therapeutics Says Psoriasis Drug Shows Deepening EfficacyBenzinga · Sep 23, 2026
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional DosingGlobeNewsWire · Sep 23, 2026
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare ConferenceGlobeNewsWire · Sep 9, 2026Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.51 | -$0.55 | Miss |
| May 13, 2026 | -$0.55 | -$0.48 | Beat |
| Mar 12, 2026 | -$0.61 | -$0.45 | Beat |
| Nov 12, 2025 | -$0.56 | -$0.55 | Beat |
| Aug 11, 2025 | -$0.48 | -$0.46 | Beat |
| May 14, 2025 | -$0.57 | -$0.40 | Beat |